SG10201911816XA - Compositions and methods comprising bupropion or related compounds and dextromethorphan - Google Patents

Compositions and methods comprising bupropion or related compounds and dextromethorphan

Info

Publication number: SG10201911816XA
Authority: SG; Singapore
Prior art keywords: dextromethorphan; bupropion; compositions; methods; related compounds
Prior art date: 2013-11-05

Application number

SG10201911816XA

Other languages

English (en)

Inventor

Herriot Tabuteau

Original Assignee

Antecip Bioventures Ii Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-11-05

Filing date

2014-11-05

Publication date

2020-01-30

2014-11-05 Application filed by Antecip Bioventures Ii Llc filed Critical Antecip Bioventures Ii Llc

2020-01-30 Publication of SG10201911816XA publication Critical patent/SG10201911816XA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Emergency Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

SG10201911816XA 2013-11-05 2014-11-05 Compositions and methods comprising bupropion or related compounds and dextromethorphan SG10201911816XA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201361900354P	2013-11-05	2013-11-05

Publications (1)

Publication Number	Publication Date
SG10201911816XA true SG10201911816XA (en)	2020-01-30

Family

ID=53042051

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
SG11201603391XA SG11201603391XA (en)	2013-11-05	2014-11-05	Compositions and methods comprising bupropion or related compounds and dextromethorphan
SG10201810888XA SG10201810888XA (en)	2013-11-05	2014-11-05	Compositions and methods comprising bupropion or related compounds and dextromethorphan
SG10201911816XA SG10201911816XA (en)	2013-11-05	2014-11-05	Compositions and methods comprising bupropion or related compounds and dextromethorphan
SG10201911808QA SG10201911808QA (en)	2013-11-05	2014-11-05	Compositions and methods comprising bupropion or related compounds and dextromethorphan

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
SG11201603391XA SG11201603391XA (en)	2013-11-05	2014-11-05	Compositions and methods comprising bupropion or related compounds and dextromethorphan
SG10201810888XA SG10201810888XA (en)	2013-11-05	2014-11-05	Compositions and methods comprising bupropion or related compounds and dextromethorphan

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG10201911808QA SG10201911808QA (en)	2013-11-05	2014-11-05	Compositions and methods comprising bupropion or related compounds and dextromethorphan

Country Status (12)

Country	Link
EP (3)	EP3981403A1 (es)
JP (4)	JP6605485B2 (es)
KR (4)	KR20230148385A (es)
CN (7)	CN110251517A (es)
AU (6)	AU2014346807B2 (es)
CA (3)	CA3154845C (es)
IL (3)	IL298972A (es)
MX (3)	MX388666B (es)
MY (1)	MY179696A (es)
NZ (5)	NZ758432A (es)
SG (4)	SG11201603391XA (es)
WO (1)	WO2015069809A1 (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11344544B2 (en)	2013-11-05	2022-05-31	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11969421B2 (en)	2013-11-05	2024-04-30	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11298351B2 (en)	2013-11-05	2022-04-12	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11191739B2 (en)	2013-11-05	2021-12-07	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11253492B2 (en)	2013-11-05	2022-02-22	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11253491B2 (en)	2013-11-05	2022-02-22	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11147808B2 (en)	2013-11-05	2021-10-19	Antecip Bioventures Ii Llc	Method of decreasing the fluctuation index of dextromethorphan
US11571417B2 (en)	2013-11-05	2023-02-07	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11534414B2 (en)	2013-11-05	2022-12-27	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11311534B2 (en)	2013-11-05	2022-04-26	Antecip Bio Ventures Ii Llc	Bupropion as a modulator of drug activity
US11541048B2 (en)	2013-11-05	2023-01-03	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11382874B2 (en)	2013-11-05	2022-07-12	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11291665B2 (en)	2013-11-05	2022-04-05	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11273133B2 (en)	2013-11-05	2022-03-15	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11590124B2 (en)	2013-11-05	2023-02-28	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11207281B2 (en)	2013-11-05	2021-12-28	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11285118B2 (en)	2013-11-05	2022-03-29	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11517543B2 (en)	2013-11-05	2022-12-06	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11234946B2 (en)	2013-11-05	2022-02-01	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11541021B2 (en)	2013-11-05	2023-01-03	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11419867B2 (en)	2013-11-05	2022-08-23	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US12109178B2 (en)	2013-11-05	2024-10-08	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11364233B2 (en)	2013-11-05	2022-06-21	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11617747B2 (en)	2013-11-05	2023-04-04	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11426370B2 (en)	2013-11-05	2022-08-30	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11617728B2 (en)	2013-11-05	2023-04-04	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11510918B2 (en)	2013-11-05	2022-11-29	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11123344B2 (en)	2013-11-05	2021-09-21	Axsome Therapeutics, Inc.	Bupropion as a modulator of drug activity
US11433067B2 (en)	2013-11-05	2022-09-06	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11357744B2 (en)	2013-11-05	2022-06-14	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11497721B2 (en)	2013-11-05	2022-11-15	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11197839B2 (en)	2013-11-05	2021-12-14	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US20200338022A1 (en)	2019-01-07	2020-10-29	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11576909B2 (en)	2013-11-05	2023-02-14	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11524007B2 (en)	2013-11-05	2022-12-13	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11298352B2 (en)	2013-11-05	2022-04-12	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11439636B1 (en)	2013-11-05	2022-09-13	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11571399B2 (en)	2013-11-05	2023-02-07	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11596627B2 (en)	2013-11-05	2023-03-07	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11426401B2 (en)	2013-11-05	2022-08-30	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11229640B2 (en)	2013-11-05	2022-01-25	Antecip Bioventures Ii Llc	Combination of dextromethorphan and bupropion for treating depression
US11129826B2 (en)	2013-11-05	2021-09-28	Axsome Therapeutics, Inc.	Bupropion as a modulator of drug activity
KR20230148385A (ko) *	2013-11-05	2023-10-24	안테씨프 바이오벤쳐스 투 엘엘씨	부프로피온 또는 관련 화합물과 덱스트로메토르판을 포함하는 조성물 및 방법
US11478468B2 (en)	2013-11-05	2022-10-25	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US20220233470A1 (en)	2013-11-05	2022-07-28	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11576877B2 (en)	2013-11-05	2023-02-14	Antecip Bioventures Ii Llc	Bupropion as modulator of drug activity
US12194006B2 (en)	2013-11-05	2025-01-14	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
TWI869633B (zh) *	2014-09-14	2025-01-11	美商阿瓦尼爾製藥股份有限公司	用於治療失智症中躁動行為之包含右旋美索芬(dextromethorphan)化合物及奎尼丁(quinidine)的藥學組成物
KR102253986B1 (ko) *	2014-11-21	2021-05-21	안테씨프 바이오벤쳐스 투 엘엘씨	에리트로히드록시부프로피온을 이용한 약물의 혈장 농도의 조절 방법
EP3432885A4 (en) *	2016-03-24	2019-11-20	Antecip Bioventures II LLC	COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFE OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS
TWI795446B (zh) *	2017-10-04	2023-03-11	美商神經治療股份有限公司	右旋美索芬(dextromethorphan)經皮輸送裝置
US20230225995A1 (en) *	2019-01-07	2023-07-20	Antecip Bioventures Ii Llc	Combination of dextromethorphan and bupropion for treating depression
JP2022516361A (ja) *	2019-01-07	2022-02-25	アンテシップバイオベンチャーズトゥーエルエルシー	うつ病の治療のためのデキストロメトルファンおよびブプロピオンの組み合わせ
CN115697314A (zh) *	2020-03-30	2023-02-03	安泰赛普生物风投二代有限责任公司	安非他酮和右美沙芬组合用于治疗神经病症的用途
EP4183391A4 (en) *	2020-07-20	2024-04-17	Shenzhen Salubris Pharmaceuticals Co., Ltd.	PHARMACEUTICAL COMPOSITION AND USE THEREOF
JP2023553393A (ja)	2020-12-01	2023-12-21	アンテシップバイオベンチャーズトゥーエルエルシー	うつ病患者の自殺リスク低減のためのブプロピオンおよびデキストロメトルファン
KR20230131927A (ko) *	2021-01-18	2023-09-14	안테씨프 바이오벤쳐스 투 엘엘씨	신경 정신 질환에 대한 항우울제와 덱스트로메토르판의조합
CN112999350A (zh) *	2021-02-23	2021-06-22	北京斯利安药业有限公司	一种药物组合物、复方制剂及其制备方法与应用
US12036191B1 (en)	2022-06-30	2024-07-16	Antecip Bioventures Ii Llc	Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
US11717518B1 (en)	2022-06-30	2023-08-08	Antecip Bioventures Ii Llc	Bupropion dosage forms with reduced food and alcohol dosing effects
US12156914B2 (en)	2022-06-30	2024-12-03	Axsome Therapeutics, Inc.	Pharmaceutical compositions comprising bupropion and cysteine
CN118785900A (zh) *	2022-06-30	2024-10-15	艾克萨姆治疗公司	包含安非他酮和半胱氨酸的药物组合物
US11730706B1 (en)	2022-07-07	2023-08-22	Antecip Bioventures Ii Llc	Treatment of depression in certain patient populations
US11844797B1 (en)	2023-04-20	2023-12-19	Antecip Bioventures Ii Llc	Combination of dextromethorphan and bupropion for treating depression
US12194036B2 (en)	2022-07-07	2025-01-14	Antecip Bioventures Ii Llc	Combination of dextromethorphan and bupropion for treating depression

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5350756A (en)	1991-06-17	1994-09-27	Smith Richard A	Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
JP2001527554A (ja) *	1997-05-07	2001-12-25	アルゴスファーマシューティカルコーポレーション	抗うつ薬とｎｍｄａレセプター拮抗薬とを組み合わせる神経障害痛の治療用組成物及び治療方法
US6207674B1 (en) *	1999-12-22	2001-03-27	Richard A. Smith	Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
US6780871B2 (en) *	2001-01-29	2004-08-24	Albany Medical College	Methods and compositions for treating addiction disorders
TWI326214B (en) *	2002-07-17	2010-06-21	Avanir Pharmaceuticals Inc	Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
KR20080097443A (ko) *	2006-02-03	2008-11-05	아바니르 파마슈티컬스	덱스트로메토판 및 퀴니딘을 포함하는, 우울, 불안 및 신경퇴행성 장애 치료용 약제학적 조성물
WO2009006194A1 (en) *	2007-06-28	2009-01-08	Avanir Pharmaceuticals	Pharmaceutical compositions for the treatment of involuntary emotional expression disorder
WO2012118562A1 (en)	2011-03-02	2012-09-07	Rhine Pharmaceuticals, Llc	Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
US20130274282A1 (en) *	2012-04-16	2013-10-17	Herriot Tabuteau	Compositions and methods comprising celecoxib or related compounds and dextromethorphan
KR20230148385A (ko) *	2013-11-05	2023-10-24	안테씨프 바이오벤쳐스 투 엘엘씨	부프로피온 또는 관련 화합물과 덱스트로메토르판을 포함하는 조성물 및 방법

2014
- 2014-11-05 KR KR1020237034772A patent/KR20230148385A/ko active Pending
- 2014-11-05 NZ NZ758432A patent/NZ758432A/en unknown
- 2014-11-05 IL IL298972A patent/IL298972A/en unknown
- 2014-11-05 SG SG11201603391XA patent/SG11201603391XA/en unknown
- 2014-11-05 EP EP21191390.0A patent/EP3981403A1/en active Pending
- 2014-11-05 CN CN201910649199.3A patent/CN110251517A/zh active Pending
- 2014-11-05 CN CN201910649207.4A patent/CN110279682A/zh active Pending
- 2014-11-05 CN CN201480072191.0A patent/CN106163522A/zh active Pending
- 2014-11-05 NZ NZ758425A patent/NZ758425A/en unknown
- 2014-11-05 CA CA3154845A patent/CA3154845C/en active Active
- 2014-11-05 CN CN201910649198.9A patent/CN110327338A/zh active Pending
- 2014-11-05 CN CN202111061795.3A patent/CN113750099A/zh active Pending
- 2014-11-05 CA CA3175703A patent/CA3175703A1/en active Pending
- 2014-11-05 MY MYPI2016701609A patent/MY179696A/en unknown
- 2014-11-05 KR KR1020167013970A patent/KR102264179B1/ko active Active
- 2014-11-05 EP EP21191393.4A patent/EP3981404A1/en active Pending
- 2014-11-05 SG SG10201810888XA patent/SG10201810888XA/en unknown
- 2014-11-05 NZ NZ758431A patent/NZ758431A/en unknown
- 2014-11-05 SG SG10201911816XA patent/SG10201911816XA/en unknown
- 2014-11-05 CA CA2929415A patent/CA2929415C/en active Active
- 2014-11-05 WO PCT/US2014/064184 patent/WO2015069809A1/en active Application Filing
- 2014-11-05 NZ NZ758428A patent/NZ758428A/en unknown
- 2014-11-05 MX MX2020004075A patent/MX388666B/es unknown
- 2014-11-05 KR KR1020227013910A patent/KR102603013B1/ko active Active
- 2014-11-05 EP EP14859589.5A patent/EP3065742A4/en active Pending
- 2014-11-05 CN CN202111061009.XA patent/CN113750098A/zh active Pending
- 2014-11-05 SG SG10201911808QA patent/SG10201911808QA/en unknown
- 2014-11-05 JP JP2016552474A patent/JP6605485B2/ja active Active
- 2014-11-05 NZ NZ719892A patent/NZ719892A/en unknown
- 2014-11-05 MX MX2016005867A patent/MX373330B/es active IP Right Grant
- 2014-11-05 CN CN202111061803.4A patent/CN113797205A/zh active Pending
- 2014-11-05 KR KR1020217016618A patent/KR20210068157A/ko not_active Ceased
- 2014-11-05 AU AU2014346807A patent/AU2014346807B2/en active Active
2016
- 2016-05-04 MX MX2021015234A patent/MX2021015234A/es unknown
- 2016-05-05 IL IL245504A patent/IL245504B/en active IP Right Grant
2018
- 2018-05-23 AU AU2018203638A patent/AU2018203638C1/en active Active
2019
- 2019-09-23 AU AU2019236614A patent/AU2019236614C1/en active Active
- 2019-10-16 JP JP2019189318A patent/JP6927601B2/ja active Active
- 2019-12-04 AU AU2019275593A patent/AU2019275593B2/en active Active
2021
- 2021-04-23 AU AU2021202497A patent/AU2021202497B2/en active Active
- 2021-06-07 IL IL283760A patent/IL283760B2/en unknown
- 2021-07-29 JP JP2021124094A patent/JP2021169527A/ja active Pending
2023
- 2023-06-01 AU AU2023203438A patent/AU2023203438A1/en active Pending
- 2023-07-27 JP JP2023122146A patent/JP2023129646A/ja active Pending

Also Published As

Publication number	Publication date
CN106163522A (zh)	2016-11-23
NZ758428A (en)	2021-07-30
NZ758431A (en)	2021-07-30
MX2016005867A (es)	2016-07-15
JP6927601B2 (ja)	2021-09-01
AU2023203438A1 (en)	2023-07-06
MX388666B (es)	2025-03-20
JP2023129646A (ja)	2023-09-14
JP2021169527A (ja)	2021-10-28
KR20230148385A (ko)	2023-10-24
NZ719892A (en)	2021-07-30
CN113797205A (zh)	2021-12-17
JP2016535786A (ja)	2016-11-17
CN110279682A (zh)	2019-09-27
AU2019275593B2 (en)	2021-01-28
CN110327338A (zh)	2019-10-15
NZ758432A (en)	2021-07-30
KR102603013B1 (ko)	2023-11-15
CA3154845A1 (en)	2015-05-14
AU2019275593A1 (en)	2020-01-02
KR20160070158A (ko)	2016-06-17
MX2020004075A (es)	2021-12-10
KR20220054909A (ko)	2022-05-03
KR102264179B1 (ko)	2021-06-11
CN113750098A (zh)	2021-12-07
JP2020023543A (ja)	2020-02-13
WO2015069809A1 (en)	2015-05-14
AU2018203638B2 (en)	2019-07-18
EP3981403A1 (en)	2022-04-13
NZ758425A (en)	2021-07-30
SG10201911808QA (en)	2020-01-30
KR20210068157A (ko)	2021-06-08
MX373330B (es)	2020-05-04
CA3154845C (en)	2023-02-28
IL245504B (en)	2021-06-30
SG10201810888XA (en)	2019-01-30
EP3065742A1 (en)	2016-09-14
MX2021015234A (es)	2022-05-26
CN113750099A (zh)	2021-12-07
AU2021202497A1 (en)	2021-05-27
AU2019236614B2 (en)	2021-07-15
AU2019236614C1 (en)	2021-10-14
IL283760B1 (en)	2023-01-01
AU2018203638A1 (en)	2018-06-14
CA2929415A1 (en)	2015-05-14
AU2014346807A1 (en)	2016-05-19
CA2929415C (en)	2023-01-03
EP3065742A4 (en)	2017-04-05
AU2021202497B2 (en)	2023-03-02
IL245504A0 (en)	2016-06-30
IL283760A (en)	2021-07-29
IL283760B2 (en)	2023-05-01
MY179696A (en)	2020-11-11
CN110251517A (zh)	2019-09-20
JP6605485B2 (ja)	2019-11-13
AU2018203638C1 (en)	2019-10-24
SG11201603391XA (en)	2016-05-30
AU2014346807B2 (en)	2018-03-22
AU2019236614A1 (en)	2019-10-17
CA3175703A1 (en)	2015-05-14
EP3981404A1 (en)	2022-04-13
IL298972A (en)	2023-02-01

Publication	Publication Date	Title
IL283760A (en)	2021-07-29	Preparations containing dextromethorphan and bupropion or similar substances and their uses
EP2838537A4 (en)	2016-03-30	COMPOSITIONS AND METHODS COMPRISING CELECOXIB OR RELATED COMPOUNDS AND DEXTROMETHORPHANE
GB2527241B (en)	2018-04-11	Compositions and methods
ZA201603237B (en)	2017-09-27	Pesticidal compositions and related methods
IL265876A (en)	2019-06-30	Preparations that include 15-ohepa and methods of using them
EP2953474A4 (en)	2016-12-28	COMPOSITIONS AND METHODS
GB201308072D0 (en)	2013-06-12	Compositions and methods
IL245035A0 (en)	2016-05-31	Pesticides and related methods
ZA201603227B (en)	2017-09-27	Pesticidal compositions and related methods
ZA201603229B (en)	2017-09-27	Pesticidal compositions and related methods
GB2519982B (en)	2016-04-27	Fungicidal composition and the use thereof
IL276126B (en)	2022-05-01	Preparations containing l-4-chloroquinonerine and their uses
GB201305813D0 (en)	2013-05-15	Compositions and methods
IL245034A0 (en)	2016-05-31	Pesticides and related methods
GB2516838B (en)	2016-09-21	Fungicidal compositions and their use
EP2964610A4 (en)	2016-11-23	VINYL SULFON-BASED 18F LABELING COMPOSITIONS AND METHOD AND USES THEREOF
ZA201603241B (en)	2017-09-27	Pesticidal compositions and related methods
GB201322456D0 (en)	2014-02-05	Radiotracer compositions and methods
GB201313803D0 (en)	2013-09-18	Fungicidal composition and method
GB201300628D0 (en)	2013-02-27	Compositions comprising 15-OHEPA and methods of using the same
GB201322617D0 (en)	2014-02-05	Methods and compositions
GB201312393D0 (en)	2013-08-21	Compositions and Methods